联环药业：他达拉非片增加2.5mg、5mg规格获批准

Core Viewpoint - The approval of additional specifications for tadalafil tablets by the National Medical Products Administration is expected to enhance the product line of the company, although it is not anticipated to have a significant impact on recent performance due to uncertainties in drug sales [1] Group 1: Product Approval - The company has received approval for tadalafil tablets in 2.5mg and 5mg specifications [1] - Tadalafil is used for the treatment of erectile dysfunction [1] Group 2: Financial Impact - The estimated sales revenue for tadalafil in domestic sample hospitals is approximately 142.72 million yuan for 2024 [1] - The company has invested around 11.95 million yuan in the research and development of this drug [1] Group 3: Future Prospects - In 2025, the company is expected to obtain 11 varieties, 13 production licenses, and 2 clinical licenses [1] - The approval is seen as a way to enrich the product line, but the sales of the drug remain uncertain [1]